<DOC>
	<DOCNO>NCT02179658</DOCNO>
	<brief_summary>The primary objective study investigate safety efficacy OPT-80 versus vancomycin subject Clostridium difficile-associated diarrhea ( CDAD ) .</brief_summary>
	<brief_title>A Study Compare Safety Efficacy OPT-80 ( Fidaxomicin ) With Vancomycin Subjects With Clostridium Difficile-associated Diarrhea ( CDAD )</brief_title>
	<detailed_description>This multicenter , double-blind , randomize , parallel group study . The subject meet inclusion criterion none exclusion criterion randomize , orally receive either OPT-80 twice daily vancomycin powder four time daily 10 day . A follow-up investigation perform 28 ( ±3 ) day completion study drug administration .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Inpatients symptom CDAD define ; ( 1 ) Diarrhea : ≥4 unformed bowel movement ( ≥200 mL unformed stool subject rectal collection device ) ( 2 ) Presence either toxin A and/or B C. difficile stool Subjects receive antibacterial ( vancomycin , metronidazole , et.al . ) aim CDAD treatment study Lifethreatening fulminant CDAD Ileus paralytic toxic megacolon Likelihood death completion study cause Concurrent use oral vancomycin , metronidazole , et.al . aim treatment CDAD The anticipated need continue antibacterial period exceed seven day provide informed consent Subjects opinion investigator require drug control diarrhea Need change dosage regimen opiates study period Need change dosage regimen probiotic product study period History/complications ulcerative colitis Crohn 's disease Multiple occurrences CDAD within past three month Hypersensitivity vancomycin Previous exposure OPT80 ( fidaxomicin ) Female patient pregnant , breastfeed possibly pregnant , wish become pregnant course study Participation clinical research study Post Marketing Clinical Trials utilize investigational agent within one month prior provide inform consent within five halflives investigational agent , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Clostridium</keyword>
	<keyword>Infections</keyword>
	<keyword>Difficile</keyword>
	<keyword>Vancomycin</keyword>
	<keyword>Fidaxomicin</keyword>
</DOC>